Please login to the form below

Not currently logged in
Email:
Password:

Xultophy

This page shows the latest Xultophy news and features for those working in and with pharma, biotech and healthcare.

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

There were also new indications approved for UCB’s Cimzia (certolizumab pegol), Amgen’s Prolia (denosumab), BMS’Sprycel (dasatinib) and Yervoy (ipilimumab), Pfizer’s Xeljanz (tofacitinib), and Novo Nordisk’s Xultophy

Latest news

  • Sanofi wins EU approval for new diabetes combination Suliqua Sanofi wins EU approval for new diabetes combination Suliqua

    same day as rival therapy Xultophy, Novo Nordisk's insulin degludec and liraglutide combination. ... In the EU, however, Xultophy has the edge as it received regulatory approval in 2014 in Europe, where it is marketed as IDegLira.

  • Sanofi launches insulin combo Soliqua in US Sanofi launches insulin combo Soliqua in US

    Sanofi launches insulin combo Soliqua in US. Diabetes drug available in pharmacies for $127 per 300 unit pen ahead of Novo Nordisk's Xultophy. ... 2016. Xultophy is already available in Europe under the IDegLira trade name, but Novo Nordisk has not yet

  • FDA clears rival diabetes combos from Sanofi and Novo Nordisk FDA clears rival diabetes combos from Sanofi and Novo Nordisk

    FDA clears rival diabetes combos from Sanofi and Novo Nordisk. Xultophy set to launch in first half of 2017 while Soliqua is intended for January roll-out. ... In the case of Xultophy, the combination is based on Novo's basal insulin Tresiba (insulin

  • Sanofi trumpets new IGlarLixi data after regulatory delay Sanofi trumpets new IGlarLixi data after regulatory delay

    Novo Nordisk's IDeglira/Xultophy (insulin degludec/liraglutide) is already on the market in Europe, but Sanofi had been hoping to get IGlarLixi to market in the US first with the ... Novo Nordisk is due to hear a verdict on Xultophy later this month.

  • Sanofi loses lead on diabetes combo IGlarLixi after FDA delay Sanofi loses lead on diabetes combo IGlarLixi after FDA delay

    Sanofi loses lead on diabetes combo IGlarLixi after FDA delay. FDA verdict on Novo Nordisk’ s rival combo Xultophy due next month . ... The FDA is due to deliver a verdict on Xultophy next month, with a decision on IGlarLixi now pushed out to the end

More from news
Approximately 13 fully matching, plus 13 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics